To witness not only the alterations of such populations but also the relevance of cell-specific reshaping to treatment’s response, we studied psoriasis patients before and after secukinumab (a human IgG1k monoclonal antibody (mAb) that selectively binds to IL-17A) or brodalumab (a human IgG2 anti-IL-17 receptor A mAb) treatment. This evidence concerns the gene IL17A and psoriasis.